NABRIVA THERAPEUTICS PLC ORDINARY SHARES, $0.01 NOMINAL VALUE PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • August 1st, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations • New York
The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Nabriva Therapeutics plc, a public limited company organized under the laws of Ireland (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters named therein, including Morgan Stanley (the “Underwriters”), of ordinary shares, nominal value $0.01 per share, in the share capital of the Company (the “Ordinary Shares”).
